The use of mobilized peripheral blood stem cells from normal donors for allografting

Stem Cells

Volumn 15, Issue 1, 1997, Pages 9-17

  Anderlini, Paolo ^a   Körbling, Martin ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Allogenic peripheral blood stem cell transplantation; Graft versus host disease; Graft versus leukemia; Recombinant human granulocyte colony stimulating factor (rHuG CSF); Stem cell mobilization

Indexed keywords

INTEGRIN; MONOCLONAL ANTIBODY; STEM CELL FACTOR; THROMBOPOIETIN;

ALLOGRAFT; ALLOTRANSPLANTATION; APHERESIS; AUTOGRAFT; GENE THERAPY; GRAFT VERSUS HOST REACTION; HEMATOLOGIC DISEASE; HUMAN; HUMAN CELL; PERIPHERAL BLOOD STEM CELL; REVIEW; STEM CELL;

EID: 0031019604     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.150009     Document Type: Review

References (56)

1. Lu L, Walker D, Broxmeyer HE et al. Characterization of adult human marrow hematopoietic progenitors highly enriched by two-color cell sorting with My 10 and major histocompatibility class II monoclonal antibodies. J Immunol 1987;139:1823-1829.
2. - progenitor cells. Blood 1991;77:1218-1227.
3. Mayani H, Lansdorp PM. Thy-1 expression is linked to functional properties of primitive hematopoietic progenitor cells from human umbilical cord blood. Blood 1994;83:2410-2417.
4. Fliedner TM, Steinbach KH. Repopulating potential of hematopoietic precursor cells. Blood Cells 1988;14:393-410.
5. dim) and lymphoid subsets, and possible predictors of engraftment and GVHD. Blood 1995;86:2842-2848.
6. + blood cells. Blood 1995;86:2500-2508.
7. To LB, Shepperd KM, Haylock DN et al. Single high doses of cyclophosphamide enable the collection of high numbers of hemopoietic stem cells from the peripheral blood. Exp Hematol 1990;18:442-447.
8. Körbling M, Przepiorka D, Gajewski J et al. With first successful allogeneic transplantation of apheresis-derived hematopoietic progenitor cells reported, can the recruitment of volunteer matched, unrelated stem cell donors be expanded substantially? Blood 1995;86:1235.
9. Peters WP, Rosner G, Ross M et al. Comparative effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. Blood 1993;81:1709-1719.
10. Lane TA, Law P, Maruyama M et al. Harvesting and enrichment of hematopoietic progenitor cells mobilized into the peripheral blood of normal donors by granulocyte-macrophage colony-stimulating factor or G-CSF: potential role in allogeneic marrow transplantation. Blood 1995;85:275-282.
11. Weaver CH, Longin K, Buckner CD et al. Lymphocyte content in peripheral blood mononuclear cells collected after administration of recombinant human granulocyte colony-stimulating factor. Bone Marrow Transplant 1994;13:411-415.
12. Prosper F, Stroncek D, Verfaillie CM. Mobilization of LTC-IC in normal donors treated with G-CSF: phenotypic analysis of mobilized PBPC. Blood 1995;86:464a.
13. + subsets in growth factor mobilized peripheral blood aphereses. Bone Marrow Transplantation (in press).
14. + peripheral blood cells from healthy adults mobilized by recombinant human granulocyte colony-stimulating factor. Blood 1994;84:2795-2801.
15. + cell counts. Blood 1994;84:541a.
16. + progenitor cells and lymphoid subsets in normal donors for allogeneic transplantation. Br J Haematol 1996;93:940-942.
17. Höglund M, Smedmyr B, Simonsson B et al. Dose-dependent mobilisation of haematopoietic progenitor cells in healthy volunteers receiving glycosylated rHuG-CSF. Bone Marrow Transplant 1996;18:19-27.
18. Wailer CF, Bertz H, Wenger MK et al. Mobilization of peripheral blood progenitor cells for allogeneic transplantation: efficacy and toxicity of a high-dose rhG-CSF regimen. Bone Marrow Transplant 1996;18:279-283.
19. Höglund M, Bengtsson M, Cour-Chabernaud V et al. Glycosylated rHuG-CSF is more potent than non-glycosylated rHuG-CSF in mobilisation of peripheral blood progenitor cells (PBPC) in healthy volunteers. Blood 1995;86:464a.
20. Kanold J, Rapatel C, Berger M et al. Use of G-CSF alone to mobilize peripheral blood stem cells for collection from children. Br J Haematol 1994;88:633-635.
21. Takaue Y, Kawano Y, Abe T et al. Collection and transplantation of peripheral blood stem cells in very small children weighing 20 kg or less. Blood 1995;86:372-380.
22. Anderlini P, Przepiorka D, Seong D et al. Clinical toxicity and laboratory effects of granulocyte-colony-stimulating factor (filgrastim) mobilization and blood stem cell apheresis from normal donors, and analysis of charges for the procedures. Transfusion 1996;36:590-595.
23. Körbling M, Chan KW, Anderlini P et al. Allogeneic peripheral blood stem cell transplantation using normal patient related pediatric donors. Bone Marrow Transplant 1996;18:885-890.
24. Moore MAS. Expansion of myeloid stem cells in culture. Semin Hematol 1995;32:183-200.
25. Pettengell R, Luft T, Henschler R et al. Direct comparison by limiting dilution analysis of long-term culture-initiating cells in human bone marrow, umbilical cord blood, and blood stem cells. Blood 1994;84:3653-3659.
26. Kaushansky K. Thrombopoietin: the primary regulator of platelet production. Blood 1995;86:419-431.
27. Molineux G, Hartley C, McElroy P et al. Megakaryocyte growth and development factor accelerates platelet recovery in peripheral blood progenitor cell transplant recipients. Blood 1996;88:366-376.
28. Geissler K, Peschel C, Niederwieser D et al. Potentiation of granulocyte colony-stimulating factor-induced mobilization of circulating progenitor cells by seven-day pretreatment with Interleukin-3. Blood 1996;87:2732-2739.
29. Huhn RD, Yurkow EJ, Tushinski R et al. Recombinant human interleukin-3 (rhIL-3) enhances the mobilization of peripheral blood progenitor cells by recombinant human granulocyte colony-stimulating factor (rhG-CSF) in normal volunteers. Exp Hematol 1996;24:839-847.
30. Geissler K, Valent P, Mayer P et al. Recombinant human interleukin-3 expands the pool of circulating hematopoietic progenitor cells in primates - synergism with recombinant human granulocyte/macrophage colony-stimulating factor. Blood 1990;75:2305-2310.
31. Hunter MG, Bawden L, Brotherton D et al. BB-10010: an active variant of human macrophage inflammatory protein-1α with improved pharmaceutical properties. Blood 1995;86:4400-4408.
32. Lord BI, Woolford LB, Wood LM et al. Mobilization of early hematopoietic progenitor cells with BB-10010: a genetically engineered variant of human macrophage inflammatory protein-1 alpha. Blood 1995;85:3412-3415.
33. Broxmeyer HE, Hague NL, Sledge GW et al. Suppression of marrow and mobilization of blood myeloid progenitors in vivo by BB10010, a genetically engineered variant of human macrophage inflammatory protein (MIP-1α), in a phase I clinical trial in patients with relapsed/refractory breast cancer. Blood 1995;86(suppl 1):12a.
34. Levesque JP, Leavesley DI, Niutta S et al. Cytokines increase human hemopoietic cell adhesiveness by activation of very late antigen (VLA)-4 and VLA-5 integrins. J Exp Med 1995;181:1805-1815.
35. McNiece IK, Langley KE, Zsebo KM. Recombinant human stem cell factor synergizes with GM-CSF, G-CSF, IL-3 and EPO to stimulate human progenitor cells of the myeloid and erythroid lineages. Exp Hematol 1991;19:226-231.
36. Andrews RG, Briddell RA, Knitter GH et al. Rapid engraftment by peripheral blood progenitor cells mobilized by recombinant human stem cell factor and recombinant human granulocyte colony-stimulating factor in nonhuman primates. Blood 1995;85:15-20.
37. McNiece I, Glaspy J, LeMaistre F et al. Effects of recombinant methionyl human stem cell factor (rhSCF) and filgrastim (rhG-CSF) on mobilization of peripheral blood progenitor cells: preliminary laboratory results from a phase I/II study. Blood 1993;82(suppl 1):84a.
38. Verfaillie C, Hurley R, Bhatia R et al. Role of bone marrow matrix in normal and abnormal hematopoiesis. Crit Rev Oncol Hematol 1994;16:201-224.
39. Simmons PJ, Masinovsky B, Longenecker BM et al. Vascular cell adhesion molecule-1 expressed by bone marrow stromal cells mediates the binding of hematopoietic progenitor cells. Blood 1992;80:388-395.
40. 4 integrin. Proc Natl Acad Sci USA 1993;90:9374-9378.
41. + cells in normal donors treated with filgrastim. Transfusion (in press).
42. Przepiorka D, Anderlini P, Ippoliti C et al. Allogeneic blood stem cell transplantation: reduction in early treatment-related morbidity and mortality for patients with advanced hematologic malignancies.Bone Marrow Transplant (in press).
43. Bjerke J, Bensinger W, Anasetti C et al. Circulating hematopoietic progenitor cell transplantation from unrelated donors: is this the future? Progressi in Ematologia Clinica 1996;15:135-141.
44. Russel JA, Brown C, Brown T et al. Allogeneic blood cell transplants for haematological malignancy: preliminary comparison of outcomes with bone marrow transplantation. Bone Marrow Transplant 1996;17:703-708.
45. Anderlini P, Przepiorka D, Khouri I et al. Chronic graft-versus-host disease after allogeneic marrow or blood stem cell transplantation. Blood 1995;86:109a.
46. Ottinger HD, Beelen DW, Scheulen B et al. Improved immune reconstitution after allotransplantation of peripheral blood stem cells instead of bone marrow. Blood 1996;88:2775-2779.
47. Anderlini P, Przepiorka D, Champlin R et al. Biologic and clinical effects of granulocyte colony-stimulating factor in normal individuals. Blood 1996;88:2819-2825.
48. Sakamaki S, Matsunaga T, Hirayama Y et al. Haematological study of healthy volunteers 5 years after G-CSF. Lancet 1995;346:1432-1433.
49. - progenitor cells, and lymphoid subsets in normal stem cell donors for allogeneic transplantation. Bone Marrow Transplant (in press).
50. Martinez C, Urbano-Ispizua A, Rozman C et al. Effects of G-CSF administration and peripheral blood progenitor cell collection in 20 healthy donors. Ann Hematol 1996;72:269-272.
51. Anderlini P, Przepiorka D, Seong D et al. Transient neutropenia in normal donors after G-CSF mobilization and stem cell apheresis. Br J Haematol 1996;94:155-158.
52. Anderlini P, Lauppe J, Przepiorka D et al. Peripheral blood stem cell apheresis in normal donors: feasibility and yield of second collections. Br J Haematol (in press).
53. Gilman P, Jackson D, Guild H. Congenital agranulocytosis: prolonged survival and terminal acute leukemia. Blood 1970;36:576-585.
54. de Planque MM, Bacigalupo A, Würsch A et al. Long-term follow-up of severe aplastic anemia patients treated with antithymocyte globulin. Br J Haematol 1989;73:121-126.
55. Hasenclever D, Sextro M. Safety of alloPBPCT donors: biometrical considerations on monitoring long term risks. Bone Marrow Transplant 1996;17(suppl 2):S28-S30.
56. Kavanagh J, Hanania EG, Giles RE et al. Genetic modification of cells used for transplant following intensive therapy for ovarian cancer and breast cancer. Blood 1996;88:272a.